Press Releases May 4, 2026 09:00 AM

22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026

22nd Century Group to report Q1 2026 financial results and provide business update on May 7, 2026

By Nina Shah XXII
22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026
XXII

22nd Century Group, Inc., a Nasdaq-listed company and pioneer in tobacco harm reduction, announced it will release its first quarter 2026 financial results on May 7, 2026, alongside a webcast featuring its CEO and CFO discussing business progress and plans for the year. The company specializes in reduced nicotine tobacco products and holds FDA authorization for its VLN® reduced nicotine combustible cigarette.

Key Points

  • 22nd Century Group will report Q1 2026 results on May 7, 2026, including a live webcast.
  • Company leads tobacco harm reduction with proprietary low nicotine tobacco technology and FDA-authorized VLN® cigarettes.
  • Focus on managing nicotine addiction and regulatory environment, while pursuing cost reduction and scalability of products.
  • Impacted sectors include tobacco industry, consumer health products, and regulated nicotine markets.

MOCKSVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction,, will host a webcast on Thursday, May 7, 2026, at 8:00 AM ET to discuss its 2026 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results, discuss progress made in the first quarter and update plans for the 2026 year.

The live and archived webcast will be accessible on the Events web page in the Company's Investor Relations section of the website, at https://ir.xxiicentury.com/events. Please access the website at least 10 minutes prior to the start of the webcast to register and, if necessary, download and install any required software.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

FDA Authorized

Our VLN® cigarette is the only low nicotine combustible cigarette authorized by the FDA in the United States.

VLN® is a registered trademark of 22nd Century Limited LLC.

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
[email protected]
214-597-8200


Risks

  • Potential regulatory enforcement actions and challenges, including uncertainties in obtaining exemptions from new regulations.
  • Actual financial and operational results may materially differ from forward-looking statements due to market, regulatory, and operational risks.
  • Dependence on broad acceptance and market adoption of reduced nicotine products amid evolving public health policies and consumer preferences.

More from Press Releases

Figure Technology Solutions Reports April 2026 Operating Data May 4, 2026 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 4, 2026 TWFG Insurance Acquires APIA Inc., Expanding Specialty MGA Capabilities and Supporting Long-Term Growth May 4, 2026 Pennant Announces First Quarter 2026 Earnings Release and Call May 4, 2026 Magna Announces 2026 Annual Meeting Results May 4, 2026